START Midwest

Midwest

Grand Rapids, MI

Sorting 5 by

Accepting patients

Cemsidomide in Combination With Elranatamab

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
  • IKZF1/3
  • Phase 1

Accepting patients

ABBV-438

A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma
  • Antibody Drug Conjugate (ADC)
  • Phase 1

Accepting patients

MOMENTUM

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
  • IKZF1/3
  • Phase 2

Accepting patients

DREAMM-20

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1/2
  • Has results

Accepting patients

OPN-662

A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
  • BET Inhibitor
  • Phase 1
  • Has results